Author(s): Jorge E. Cortes, Bruno C. Medeiros, Geoffrey L. Uy, et al. Abstract: PF239 Session topic: 4. Acute myeloid leukemia – Clinical Background CPX-351, a liposomal co-encapsulation of cytarabine and daunorubicin at a synergistic 5:1 molar ratio, is approved in the United States for the treatment of adults with newly diagnosed therapy-related AML or...
Pro zobrazení tohoto obsahu je třeba být přihlášen.